{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:23:00Z","timestamp":1762917780038,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2017,3,20]]},"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To compare the efficacy and safety of intravaginal misoprostol 200 \u00b5g, 400 \u00b5g and gemeprost regimens for second-trimester termination of pregnancy (TOP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A three- armed randomi sed controlled trial (Clinical Trial Certificate 1100015) where 116 women undergoing second-trimester TOP were given intravaginal misoprostol 200 \u00b5 g (<jats:italic>n<\/jats:italic>=37), misoprostol 400 \u00b5g (<jats:italic>n<\/jats:italic>=40) or gemeprost 1 mg (<jats:italic>n<\/jats:italic>=39) at 4- hour intervals until abortion occurred with a maximum of five doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The misoprostol 400 \u00b5g group had the highest incidence of successful abortions (92.5%) compared to the misoprostol 200 \u00b5g (70.3%; <jats:italic>p<\/jats:italic>=0.017) and gemeprost 1 mg (74.4%; <jats:italic>p<\/jats:italic>=0.037) within 48 hours. There was no significant difference in abortion rate between misoprostol 200 \u00b5g and gemeprost. The misoprostol 400 \u00b5g group had the highest incidence of fever (70.0%) compared to misoprostol 200 \u00b5g (24.3%; <jats:italic>p<\/jats:italic>&lt;0.001) and gemeprost 1 mg (46.2%; <jats:italic>p<\/jats:italic>=0.041). The gemeprost group had the highest incidence of diarrhoea (38.5%) compared to misoprostol 400 \u00b5g (10.0%; <jats:italic>p<\/jats:italic>=0.004) and misoprostol 200 \u00b5g (8.1%; <jats:italic>p<\/jats:italic>=0.003) groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intravaginal misoprostol 400 \u00b5 g at 4- hour intervals was the most effective regimen but was associated with a high incidence of fever. Misoprostol 200 \u00b5g demonstrated similar effectiveness as gemeprost and had lower incidence of diarrhoea. Gemeprost should not be first line for medical therapy given the cost, storage requirements and lower efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jfprhc-2016-101652","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T20:50:13Z","timestamp":1492807813000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing two regimens of intravaginal misoprostol with intravaginal gemeprost for second-trimester pregnancy termination: a randomised controlled trial"],"prefix":"10.1136","volume":"43","author":[{"given":"Daniel Seow Choon","family":"Koh","sequence":"first","affiliation":[{"name":"Associate Consultant, Division of Obstetrics & Gynecology, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Pei Jing","family":"Ang","sequence":"additional","affiliation":[{"name":"Pharmacist, Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurja Chua","family":"Coyuco","sequence":"additional","affiliation":[{"name":"Pharmacist, Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua Zhen","family":"Teo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacist, Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Huang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacist, Department of Pharmacy, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Wei","sequence":"additional","affiliation":[{"name":"Executive, Department of Maternal Fetal Medicine, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mor Jack","family":"Ng","sequence":"additional","affiliation":[{"name":"Manager, Division of Obstetrics & Gynecology, OBGYN Academic Clinical Program, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serene Liqing","family":"Lim","sequence":"additional","affiliation":[{"name":"Associate Consultant, Division of Surgery, Singapore General Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok Hian","family":"Tan","sequence":"additional","affiliation":[{"name":"Senior Consultant, Division of Obstetrics & Gynecology, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"2025090510330814000_43.4.252.1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(88)90207-X"},{"key":"2025090510330814000_43.4.252.2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(87)90268-1"},{"key":"2025090510330814000_43.4.252.3","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.ijgo.2007.09.003","article-title":"Misoprostol in obstetrics and gynecology","volume":"99","author":"Weeks","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"key":"2025090510330814000_43.4.252.4","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dml049"},{"key":"2025090510330814000_43.4.252.5","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.ijgo.2007.09.002","article-title":"Misoprostol for reproductive health: dosage recommendations","volume":"99","author":"Shaw","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"key":"2025090510330814000_43.4.252.6","first-page":"CD005216","article-title":"Medical methods for mid-trimester termination of pregnancy","volume":"1","author":"Wildschut","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090510330814000_43.4.252.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(98)00099-7"},{"key":"2025090510330814000_43.4.252.8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.contraception.2008.10.009","article-title":"Misoprostol for termination of pregnancy with intrauterine fetal demise in the second and third trimester of pregnancy - a systematic review","volume":"79","author":"G\u00f3mez Ponce de Le\u00f3n","year":"2009","journal-title":"Contraception"},{"key":"2025090510330814000_43.4.252.9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijgo.2005.11.010","article-title":"Vaginal vs. oral misoprostol for mid-trimester abortion","volume":"92","author":"Nigam","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"2025090510330814000_43.4.252.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.09.004"},{"key":"2025090510330814000_43.4.252.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440107"},{"key":"2025090510330814000_43.4.252.12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12884-016-1188-1","article-title":"Association between infection and fever in terminations of pregnancy using misoprostol: a retrospective cohort study","volume":"17","author":"Nijman","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025090510330814000_43.4.252.13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.ajog.2005.02.082","article-title":"A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy","volume":"193","author":"Su","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2025090510330814000_43.4.252.14","first-page":"159","article-title":"Uses of misoprostol in obstetrics and gynecology","volume":"2","author":"Allen","year":"2009","journal-title":"Rev Obstet Gynecol"},{"key":"2025090510330814000_43.4.252.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6661(199805\/06)7:3<115::AID-MFM3>3.0.CO;2-N"},{"key":"2025090510330814000_43.4.252.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00222.x"},{"key":"2025090510330814000_43.4.252.17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.3.709"},{"key":"2025090510330814000_43.4.252.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00491-2"},{"key":"2025090510330814000_43.4.252.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00111-7"},{"key":"2025090510330814000_43.4.252.20","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.121085"},{"key":"2025090510330814000_43.4.252.21","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG). The Care of Women Requesting Induced Abortion. Evidence-based Clinical Guideline Number 7. London, UK: RCOG, 2011. Available at. https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/abortion-guideline_web_1.pdf (accessed 6 February 2017)."},{"key":"2025090510330814000_43.4.252.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000289577.32274.a5"},{"key":"2025090510330814000_43.4.252.23","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318227214e"},{"key":"2025090510330814000_43.4.252.24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/AOG.0b013e31819dbfe2","article-title":"Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review","volume":"113","author":"Goyal","year":"2009","journal-title":"Obstet Gynecol"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jfprhc-2016-101652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:53:48Z","timestamp":1757094828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/jfprhc-2016-101652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,10,10]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/jfprhc-2016-101652"],"URL":"https:\/\/doi.org\/10.1136\/jfprhc-2016-101652","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"type":"print","value":"1471-1893"},{"type":"electronic","value":"2045-2098"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}